Trump Rebuked Over Canada Tariffs as Midterm Anxieties Grow | Daybreak Europe 02/12/2026
Watch on YouTube ↗  |  February 12, 2026 at 07:44 UTC  |  46:44  |  Bloomberg Markets
Speakers
Lizzy Burden — Anchor, Bloomberg Daybreak Europe
Mark Cranfield — Cross Asset Strategist, Bloomberg
Freya Beamish — Macro Economist
Roland Busch — CEO, Siemens
Yves Chapot — CFO, Michelin
Annabelle Drou — Asia Reporter, Bloomberg
Will Wilkes — Reporter, Bloomberg Frankfurt

Summary

  • Asia Decoupling: Asian equities are outperforming the US significantly (MSCI Asia +13% YTD vs S&P +1%), driven by the AI supply chain and memory chip tightness, specifically benefiting Korean markets.
  • Industrial Bifurcation: A clear divergence is emerging within European industrials. "Smart" industrials (Siemens) exposed to data centers and software are booming, while legacy "metal" industrials (Mercedes) are crushed by Chinese competition and margin compression.
  • Rate Cut Repricing: Strong US jobs data has forced traders to push Fed cut expectations from June to July, causing a spike in front-end Treasury yields.
  • GLP-1 Evolution: Novo Nordisk is successfully pivoting from injections to pills (Wegovy oral), aiming for mass adoption while legally attacking compounding pharmacies to protect IP moats.
Trade Ideas
Ticker Direction Speaker Thesis Time
LONG Annabelle Drou
Asia Reporter, Bloomberg
Samsung shares rose 7% and the KOSPI rose 3% following Micron's comments about "tightness" in the memory chip supply chain. The AI boom is creating a structural shortage in high-bandwidth memory. While US tech is flat due to rate fears, Asian hardware suppliers are catching the "second wave" of AI capital expenditure. Long memory sector as pricing power returns to suppliers. Global trade war escalation impacting semiconductor exports.
LONG Roland Busch
President and CEO, Siemens
Siemens raised guidance and reported 37% growth in software revenue. The CEO explicitly stated, "Data center... very strong growth" and "Automation is coming back." Siemens is effectively transitioning from a cyclical industrial manufacturer to a secular growth "Industrial Tech" play. They are capturing the CapEx spend on data centers and electrification, insulating them from the weakness in the automotive sector. Long Siemens as a derivative play on AI infrastructure and grid modernization. Continued weakness in their legacy machine-building segment.
AVOID William Wilkes
Reporter, Bloomberg
Mercedes missed estimates, margins are under pressure, and they face "fierce competition" in China, their most important market. Legacy auto is in a "death spiral" of high costs and declining pricing power. Unlike Siemens, which pivoted to software, Mercedes is stuck with hardware exposure in a market (China) where domestic brands are dominating. Avoid or Short. The luxury strategy is failing to offset volume declines. Unexpected stimulus in China boosting luxury car purchases.
SHORT Mark Cranfield
Cross Asset Strategist, Bloomberg
A surprisingly strong US jobs report caused yields to surge as traders moved Fed cut expectations from June to July. The bond market is trapped in volatility. The data is contradictory (weak private jobs vs. strong payrolls), but the "higher for longer" narrative is gaining traction again. Traders are being forced to become "day traders," making holding duration dangerous. Short/Underweight duration until data trends clarify. A sudden weak CPI print could reverse yields rapidly.
JPY
LONG Mark Cranfield
Cross Asset Strategist, Bloomberg
The Yen is strengthening (153 per dollar) despite strong US data, showing "underlying desire to sell the US Dollar" and demand for Yen regardless of macro prints. The market is structurally rotating into the Yen, likely due to the "Renaissance" in the Japanese economy and a flight to safety ahead of US political volatility (tariffs/midterms). Long JPY as a hedge against US dollar volatility. Bank of Japan failing to normalize rates further. 12:36
NVO
LONG Lars Fruergaard Jørgensen
Former CEO, Novo Nordisk
246,000 people are already on the Wegovy pill just five weeks after launch. The CEO is aggressively litigating against compounding pharmacies using unauthorized API. The shift from injection to oral delivery removes the biggest friction point for patients (needles), expanding the TAM (Total Addressable Market) significantly. Legal wins against compounders will restore pricing power and volume to the official product. Long NVO on the successful form-factor pivot. US government pressure on drug pricing. 38:20